# Dose-Escalation, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy Male Adults

> **NCT06095973** · PHASE1 · COMPLETED · sponsor: **G2GBio, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Pain, Postoperative

## Interventions

- **DRUG:** GB-6002
- **DRUG:** Placebo
- **DRUG:** Naropin injection

## Key facts

- **NCT ID:** NCT06095973
- **Lead sponsor:** G2GBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-24
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06095973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06095973, "Dose-Escalation, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy Male Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06095973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*